ConductScience.org, home

Comparison · NCT04579393-3a9330fa

Fostamatinib With Standard of Care for Treatment of COVID-19 vs Placebo With Standard of Care for Treatment of COVID-19: Number of Participants Who Progress to Mechanical Ventilation

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Fostamatinib With Standard of Care for Treatment of COVID-19 vs Placebo With Standard of Care for Treatment of COVID-19: Number of Participants Who Progress to Mechanical Ventilation. Trial comparisons, record NCT04579393-3a9330fa. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04579393-3a9330fa

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.03570.006330.177wilson
Risk in group 20.07410.02060.234wilson
Risk difference, group 1 minus group 2-0.0384-0.2010.113newcombe hybrid score
Risk ratio, group 1 over group 20.4820.04645.01log
Odds ratio, group 1 over group 20.4630.03955.43log
Number needed to treat, for one fewer participant with the outcome on Fostamatinib With Standard of Care for Treatment of COVID-19 than on Placebo With Standard of Care for Treatment of COVID-1926.1from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Fostamatinib With Standard of Care for Treatment of COVID-19Fostamatinib, will be administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.128OG000
Group 2Placebo With Standard of Care for Treatment of COVID-19Placebo tablets to match fostamatinib 150 mg will be provided and administered orally at a dose of 150 mg twice daily for 14 days or 28 doses.227OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Progress to Mechanical Ventilation
Description
Number of participants who progress to mechanical ventilation by day 29
Time frame
day 29
Population
Participants who were not receiving mechanical ventilation at baseline

Source ClinicalTrials.gov

Trial

Title
Fostamatinib for Hospitalized Adults With COVID-19
NCT number
NCT04579393
Phases
PHASE2
Conditions
Coronavirus Disease 2019
Interventions
Placebo, fostamatinib
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Results first posted
2022-03-02

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04579393-3a9330fa